[Case of a patient with inflammatory breast cancer who responded to preoperative chemotherapy with paclitaxel plus bevacizumab and could subsequently undergo surgery].

Abstract

A 58-year-old woman observed swelling in her left breast a few weeks prior to presentation. Rigidity in the D area, breast warmth, swelling, and a peau d'orange appearance in the whole left breast was observed. She was diagnosed with inflammatory breast cancer (luminal A type) T4dN2M0, Stage IIIB. The patient underwent primary systemic therapy with 7 courses of FEC. Following FEC treatment, the disease was stable. We subsequently administered 4 courses of bevacizumab plus paclitaxel combination therapy. The patient exhibited a partial response to FEC chemotherapy. Thereafter, a left mastectomy with level II axillary lymph node dissection was performed. At present, 1 year after surgery, the patient is alive with no recurrence. We conclude that the combination therapy of bevacizumab plus paclitaxel is a useful treatment for inflammatory breast cancer.

• Authors: Shinichiro Kashiwagi, Sae Ishihara, Mariko Ishii, Yuka Asano, Mao Watanabe, Tamami Morisaki, Naoki Aomatsu, Satoru Noda, Hidemi Kawajiri, Taeko Nakano, Noriko Kawakami, Yasuko Mitsukawa, Tsutomu Takashima, Naoyoshi Onoda, Tetsuro Ishikawa, Kosei Hirakawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 40 Issue 12 Pg. 2384-6 (Nov 2013) ISSN: 0385-0684 [Print] Japan
• PMID: 24394120 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal, Humanized
• Bevacizumab
• Paclitaxel

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Bevacizumab
• Carcinoma, Ductal, Breast (drug therapy, surgery)
• Female
• Humans
• Inflammatory Breast Neoplasms (drug therapy, pathology, surgery)
• Mastectomy
• Middle Aged
• Neoadjuvant Therapy
• Paclitaxel (administration & dosage)